

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 August 2005 (04.08.2005)

PCT

(10) International Publication Number  
**WO 2005/070957 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 14/00**,  
14/02, C07H 21/00, 21/04, C12Q 1/00, 1/70, C12N 9/00

(21) International Application Number:  
PCT/US2005/000292

(22) International Filing Date: 6 January 2005 (06.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/535,708 9 January 2004 (09.01.2004) US

(71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GRAHAM, Donald,**

**J.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **SIMCOE, Amy, L.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **LUDMERER, Steven, W.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **FLORES, Osvaldo, A.** [CL/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **LAFEMINA, Robert, L.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: HCV RNA-DEPENDENT RNA POLYMERASE

MSMSYTWGALITPCAESEKLPINPLNSLLRYHNNVYTSSTASLRANKVTFDMQVLSYDYSVLRKDKL  
AASKVTAALLTTEACDLTPHSAKSKYGFAGQVNSHASKAVNNISVWEDLLEDSDTPTPTIMAKNEVFCV  
DPTGGKKAARLIVYDGLVRCCKMALDYDTQKLPQAVNGASVGFQYSFAQVVEFLAKAWKEDPMGFSYDT  
RCFDSVTERDITREESIYQCSLQPEAKRTVHSILTEPLVGGPMTHSKGQCGYRCHASGVLTSMGNTTTC  
YKALAAKAGLITAPMVGCDGLVLSGGQSDVIMHAFITAMNINIASVQGLHAYVDELLITSCSN  
VSVADGNGKRYLLTRDPTPLARANKTVRHTPVNSHGNIIQYATPITWVRMIMTHFSSILQSQEQLKAL  
DFDIYGVTVSPLDPLALIERLGLDASLHGYSPVELRVGACLRKGLVPLARWRHRAVRAKLIAGGK  
AALCGYILFPAWVKTKLTPPLPAKLDLSGWTFVGGGGDIYBSVSHARF

A

MSMSYTWGALITPCAESEKLPINPLNSLLRYHNNVYTSSTASLRANKVTFDMQVLSYDYSVLRKDKL  
AASKVTAALLTTEACDLTPHSAKSKYGFAGQVNSHASKAVNNISVWEDLLEDSDTPTPTIMAKNEVFCV  
DPTGGKKAARLIVYDGLVRCCKMALDYDTQKLPQAVNGASVGFQYSFAQVVEFLAKAWKEDPMGFSYDT  
RCFDSVTERDITREESIYQCSLQPEAKRTVHSILTEPLVGGPMTHSKGQCGYRCHASGVLTSMGNTTTC  
YKALAAKAGLITAPMVGCDGLVLSGGQSDVIMHAFITAMNINIASVQGLHAYVDELLITSCSN  
VSVADGNGKRYLLTRDPTPLARANKTVRHTPVNSHGNIIQYATPITWVRMIMTHFSSILQSQEQLKAL  
DFDIYGVTVSPLDPLALIERLGLDASLHGYSPVELRVGACLRKGLVPLARWRHRAVRAKLIAGGK  
AALCGYILFPAWVKTKLTPPLPAKLDLSGWTFVGGGGDIYBSVSHARF

B

MSMSYTWGALITPCAESEKLPINPLNSLLRYHNNVYTSSTASLRANKVTFDMQVLSYDYSVLRKDKL  
AASKVTAALLTTEACDLTPHSAKSKYGFAGQVNSHASKAVNNISVWEDLLEDSDTPTPTIMAKNEVFCV  
DPTGGKKAARLIVYDGLVRCCKMALDYDTQKLPQAVNGASVGFQYSFAQVVEFLAKAWKEDPMGFSYDT  
RCFDSVTERDITREESIYQCSLQPEAKRTVHSILTEPLVGGPMTHSKGQCGYRCHASGVLTSMGNTTTC  
YKALAAKAGLITAPMVGCDGLVLSGGQSDVIMHAFITAMNINIASVQGLHAYVDELLITSCSN  
VSVADGNGKRYLLTRDPTPLARANKTVRHTPVNSHGNIIQYATPITWVRMIMTHFSSILQSQEQLKAL  
DFDIYGVTVSPLDPLALIERLGLDASLHGYSPVELRVGACLRKGLVPLARWRHRAVRAKLIAGGK  
AALCGYILFPAWVKTKLTPPLPAKLDLSGWTFVGGGGDIYBSVSHARF

C

MSMSYTWGALITPCAESEKLPINPLNSLLRYHNNVYTSSTASLRANKVTFDMQVLSYDYSVLRKDKL  
AASKVTAALLTTEACDLTPHSAKSKYGFAGQVNSHASKAVNNISVWEDLLEDSDTPTPTIMAKNEVFCV  
DPTGGKKAARLIVYDGLVRCCKMALDYDTQKLPQAVNGASVGFQYSFAQVVEFLAKAWKEDPMGFSYDT  
RCFDSVTERDITREESIYQCSLQPEAKRTVHSILTEPLVGGPMTHSKGQCGYRCHASGVLTSMGNTTTC  
YKALAAKAGLITAPMVGCDGLVLSGGQSDVIMHAFITAMNINIASVQGLHAYVDELLITSCSN  
VSVADGNGKRYLLTRDPTPLARANKTVRHTPVNSHGNIIQYATPITWVRMIMTHFSSILQSQEQLKAL  
DFDIYGVTVSPLDPLALIERLGLDASLHGYSPVELRVGACLRKGLVPLARWRHRAVRAKLIAGGK  
AALCGYILFPAWVKTKLTPPLPAKLDLSGWTFVGGGGDIYBSVSHARF

D

MSMSYTWGALITPCAESEKLPINPLNSLLRYHNNVYTSSTASLRANKVTFDMQVLSYDYSVLRKDKL  
AASKVTAALLTTEACDLTPHSAKSKYGFAGQVNSHASKAVNNISVWEDLLEDSDTPTPTIMAKNEVFCV  
DPTGGKKAARLIVYDGLVRCCKMALDYDTQKLPQAVNGASVGFQYSFAQVVEFLAKAWKEDPMGFSYDT  
RCFDSVTERDITREESIYQCSLQPEAKRTVHSILTEPLVGGPMTHSKGQCGYRCHASGVLTSMGNTTTC  
YKALAAKAGLITAPMVGCDGLVLSGGQSDVIMHAFITAMNINIASVQGLHAYVDELLITSCSN  
VSVADGNGKRYLLTRDPTPLARANKTVRHTPVNSHGNIIQYATPITWVRMIMTHFSSILQSQEQLKAL  
DFDIYGVTVSPLDPLALIERLGLDASLHGYSPVELRVGACLRKGLVPLARWRHRAVRAKLIAGGK  
AALCGYILFPAWVKTKLTPPLPAKLDLSGWTFVGGGGDIYBSVSHARF

E

(57) Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.

WO 2005/070957 A1



MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**(84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.